Free Trial

AbbVie (ABBV) Stock Price, News & Analysis

AbbVie logo
$221.93 +1.12 (+0.51%)
Closing price 03:59 PM Eastern
Extended Trading
$221.84 -0.09 (-0.04%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About AbbVie Stock (NYSE:ABBV)

Advanced

Key Stats

Today's Range
$219.92
$222.07
50-Day Range
$184.77
$221.93
52-Week Range
$163.81
$222.07
Volume
4.44 million shs
Average Volume
4.29 million shs
Market Capitalization
$392.05 billion
P/E Ratio
20.85
Dividend Yield
2.96%
Price Target
$222.68
Consensus Rating
Moderate Buy

Company Overview

AbbVie Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
97th Percentile Overall Score

ABBV MarketRank™: 

AbbVie scored higher than 97% of companies evaluated by MarketBeat, and ranked 57th out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    AbbVie has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 17 buy ratings, 6 hold ratings, and no sell ratings.

  • Upside/Downside

    The consensus price target for AbbVie is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    AbbVie has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about AbbVie's stock forecast and price target.
  • Earnings Growth

    Earnings for AbbVie are expected to grow by 13.57% in the coming year, from $12.31 to $13.98 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of AbbVie is 20.85, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 281.50.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of AbbVie is 20.85, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 76.93.

  • Price to Earnings Growth Ratio

    AbbVie has a PEG Ratio of 1.32. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    AbbVie has a P/B Ratio of 116.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about AbbVie's valuation and earnings.
  • Percentage of Shares Shorted

    0.88% of the float of AbbVie has been sold short.
  • Short Interest Ratio / Days to Cover

    AbbVie has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in AbbVie has recently decreased by 9.41%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    AbbVie pays a meaningful dividend of 2.97%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    AbbVie has been increasing its dividend for 53 years.

  • Dividend Coverage

    The dividend payout ratio of AbbVie is 312.38%. Payout ratios above 75% are not desirable because they may not be sustainable.

  • Dividend Sustainability

    Based on earnings estimates, AbbVie will have a dividend payout ratio of 46.92% next year. This indicates that AbbVie will be able to sustain or increase its dividend.

  • Read more about AbbVie's dividend.
  • Percentage of Shares Shorted

    0.88% of the float of AbbVie has been sold short.
  • Short Interest Ratio / Days to Cover

    AbbVie has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in AbbVie has recently decreased by 9.41%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    AbbVie has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 127 news articles for AbbVie this week, compared to 53 articles on an average week.
  • Search Interest

    Only 118 people have searched for ABBV on MarketBeat in the last 30 days. This is a decrease of -34% compared to the previous 30 days.
  • MarketBeat Follows

    71 people have added AbbVie to their MarketBeat watchlist in the last 30 days. This is an increase of 109% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, AbbVie insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,046,246.00 in company stock.

  • Percentage Held by Insiders

    Only 0.25% of the stock of AbbVie is held by insiders.

  • Percentage Held by Institutions

    70.23% of the stock of AbbVie is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about AbbVie's insider trading history.
Receive ABBV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ABBV Stock News Headlines

Stethoscope on desk
As the Market Rotates, This Healthcare ETF Is Leading the Way (ABBV)
Health care saw some of the worst losses this year. But as the calendar turned to August, it's been leading the market higher. This ETF provides exposure.
AbbVie stock hits all-time high at 221.8 USD
Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.tc pixel
AbbVie, Novo get Berenberg boost while Lilly, Merck face downgrades
Should You Buy This Blue-Chip Dividend Stock at Record Highs?
See More Headlines

ABBV Stock Analysis - Frequently Asked Questions

AbbVie's stock was trading at $177.70 at the beginning of the year. Since then, ABBV shares have increased by 24.9% and is now trading at $221.93.

AbbVie Inc. (NYSE:ABBV) announced its quarterly earnings results on Thursday, July, 31st. The company reported $2.97 earnings per share for the quarter, missing analysts' consensus estimates of $3.24 by $0.27. The firm's revenue was up 6.6% on a year-over-year basis.
Read the conference call transcript
.

The following companies are subsidiaries of AbbVie: Mavupharma, Allergan, Stem CentRx, Pharmacyclics Inc, ImmuVen, AbbVie AB, AbbVie AG, and others.

AbbVie's top institutional shareholders include Vanguard Group Inc. (10.04%), State Street Corp (4.53%), Geode Capital Management LLC (2.22%) and Charles Schwab Investment Management Inc. (1.52%). Insiders that own company stock include Richard A Gonzalez, Azita Saleki-Gerhardt, Robert A Michael, Nicholas Donoghoe, Jeffrey Ryan Stewart, Timothy J Richmond, Roxanne S Austin, Carrie C Strom, Elaine K Sorg, Scott T Reents, Perry C Siatis and Kevin K Buckbee.
View institutional ownership trends
.

Shares of ABBV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that AbbVie investors own include NVIDIA (NVDA), Verizon Communications (VZ), JPMorgan Chase & Co. (JPM), Chevron (CVX), Vanguard Short-Term Inflation-Protected Securities ETF (VTIP), Salesforce (CRM) and Intact Financial (IFC).

Company Calendar

Record date for 8/15 Dividend
7/15/2025
Ex-Dividend for 8/15 Dividend
7/15/2025
Last Earnings
7/31/2025
Dividend Payable
8/15/2025
Today
9/18/2025
Record date for 11/14 Dividend
10/15/2025
Ex-Dividend for 11/14 Dividend
10/15/2025
Next Earnings (Estimated)
10/29/2025
Dividend Payable
11/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Large Cap Pharma
Sub-Industry
Pharmaceuticals
Current Symbol
NYSE:ABBV
CIK
1551152
Employees
55,000
Year Founded
2013

Price Target and Rating

High Price Target
$270.00
Low Price Target
$190.00
Potential Upside/Downside
+0.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.93
Research Coverage
27 Analysts

Profitability

EPS (Trailing Twelve Months)
$2.10
Trailing P/E Ratio
105.68
Forward P/E Ratio
18.03
P/E Growth
1.39
Net Income
$4.28 billion
Net Margins
6.45%
Pretax Margin
5.19%
Return on Equity
699.66%
Return on Assets
13.64%

Debt

Debt-to-Equity Ratio
44.14
Current Ratio
0.74
Quick Ratio
0.61

Sales & Book Value

Annual Sales
$58.33 billion
Price / Sales
6.72
Cash Flow
$15.33 per share
Price / Cash Flow
14.48
Book Value
$1.90 per share
Price / Book
116.81

Miscellaneous

Outstanding Shares
1,766,558,000
Free Float
1,762,142,000
Market Cap
$392.05 billion
Optionable
Optionable
Beta
0.53

Social Links

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NYSE:ABBV) was last updated on 9/18/2025 by MarketBeat.com Staff
From Our Partners